Intellia Therapeutics (NTLA) Operating Margin (2016 - 2025)
Intellia Therapeutics (NTLA) has disclosed Operating Margin for 11 consecutive years, with 428.86% as the latest value for Q4 2025.
- On a quarterly basis, Operating Margin rose 63101.0% to 428.86% in Q4 2025 year-over-year; TTM through Dec 2025 was 651.67%, a 27143.0% increase, with the full-year FY2025 number at 651.67%, up 27143.0% from a year prior.
- Operating Margin was 428.86% for Q4 2025 at Intellia Therapeutics, up from 808.86% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 7297.44% in Q4 2023 to a low of 23997.67% in Q3 2021.
- A 5-year average of 1671.09% and a median of 809.97% in 2022 define the central range for Operating Margin.
- Peak YoY movement for Operating Margin: crashed -2387120bps in 2021, then soared 2320217bps in 2022.
- Intellia Therapeutics' Operating Margin stood at 625.6% in 2021, then fell by -30bps to 811.07% in 2022, then surged by 1000bps to 7297.44% in 2023, then tumbled by -115bps to 1059.86% in 2024, then soared by 60bps to 428.86% in 2025.
- Per Business Quant, the three most recent readings for NTLA's Operating Margin are 428.86% (Q4 2025), 808.86% (Q3 2025), and 772.17% (Q2 2025).